As of Friday close, Abbott Laboratories’s (NYSE:ABT) stock was down -$0.78, moving down -0.79 percent to $98.15. The average number of shares traded per day over the past five days has been 4,002,200 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.59 fall in that time frame. In the last twenty days, the average volume was 4,227,630, while in the previous 50 days, it was 4,408,884.
Since last month, ABT stock retreated -6.64%. Shares of the company fell to $98.01 on 09/22/23, the lowest level in the past month. A 52-week high of $115.83 was reached on 07/24/23 after having rallying from a 52-week low of $93.25. Since the beginning of this year, ABT’s stock price has dropped by -10.60% or -$11.64, and marked a new high 7 times. However, the stock has declined by -15.26% since its 52-week high.
ABT stock investors should be aware that Abbott Laboratories (ABT) stock had its last reported insider trading activity 46 days ago on Aug 08. Wainer Andrea F, the EXECUTIVE VICE PRESIDENT of the company, disposed of 10,400 shares for $105.03 on Aug 08. It resulted in a $1,092,297 divestment by the insider. STARKS DANIEL J sold 50,000 shares at an average price of $113.76 on Jul 27. The insider now owns 6,775,316 shares following the transaction. On May 02, Director STARKS DANIEL J sold 50,000 shares at $111.02 apiece. The transaction was valued at $5,551,193.
Valuation Metrics
Right now, Abbott Laboratories (ABT) has a P/E ratio of about 33.37. The stock’s beta is 0.68. Besides these, the trailing price-to-sales (P/S) ratio of 4.27, the price-to-book (PB) ratio of 4.60, and the price-to-cash flow ratio of 31.31 may also be considered.
The latest dividend of $0.51 per share was paid out, remained unchanged from last year’s $0.51.
Financial Health
In the recent quarter, Abbott Laboratories’s quick ratio stood at 1.20, while its current ratio was 1.60, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the recent quarter was 0.39, and the total debt-to-equity ratio was 0.45. On the profitability front, the trailing twelve-month gross margin is 55.20% percent. In the recent year, EBITDA margin amounted to 26.64%, whereas operating margins totaled 15.20%. Based on annual data, ABT earned $24.51 billion in gross profit and brought in $43.65 billion in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 13.00%. Return on equity (ROE) for the past 12 months was 14.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. ABT’s revenue fell -12.82% to $9.75 billion during the quarter, while net income inched up to $9.98 billion. During the quarter, the company generated $2.34 billion in EBITDA. The liabilities of Abbott Laboratories were 35.95 billion at the end of its most recent quarter, and its total debt was $16.99 billion. The value of shareholders’ equity is $1.74 billion.
Technical Picture
This quick technical analysis looks at Abbott Laboratories’s (ABT) price momentum. With a historical volatility rate of 6.58%, the RSI 9-day stood at 21.99% on 22 September.
With respect to its five-day moving average, the current Abbott Laboratories price is down by -3.53% percent or -$3.59. At present, ABT shares trade -5.40% below its 20-day simple moving average and -11.66% percent below its 100-day simple moving average. However, the stock is currently trading approximately -8.90% below its SMA50 and -6.89% below its SMA200.
Stochastic coefficient K was 4.88% and Stochastic coefficient D was 10.50%, while ATR was 1.46. Given the Stochastic reading of 2.41% for the 14-day period, the RSI (14) reading has been calculated as 28.37%. As of today, the MACD Oscillator reading stands at -1.83, while the 14-day reading stands at -1.94.
Analyst Ratings
Wolfe Research upgraded its rating on Abbott Laboratories (NYSE: ABT) to a Peer perform in a note to investors on July 21, 2023. The analysts firm previously had an Underperform rating on the stock.Abbott Laboratories (ABT) has been rated Overweight by analysts. According to 0 brokerage firms, ABT is a sell, and 7 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 5 analysts rate Abbott Laboratories stock as buy, with 13 recommending it as overweight.
With a median target price of $123.00, the current consensus forecast for the stock is $112.00 – $136.00. Based on these forecasts, analysts predict Abbott Laboratories (ABT) will achieve an average price target of $124.02.
